[Impact of a geriatric oncology tumor-board on medical decision-making in patients aged 70 and over with cancer].

INTRODUCTION

A Geriatric Oncology Multidisciplinary Team (GO-MDT) board was established at Gustave Roussy to optimize treatment decision-making for patients aged≥70 years with cancer. The aim of this study was to evaluate its impact on treatment decisions.

METHODS

We conducted a retrospective single-center study including patients aged≥70 years with either a hematological malignancy or a solid tumor who were discussed at the GO-MDT between October 2022 and October 2023. The primary endpoint was the distribution of GO-MDT recommendations regarding the proposed treatment (favorable, favorable with adjustment, or unfavorable). Secondary endpoints were the concordance between GO-MDT recommendations and the treatment ultimately delivered when treatment modification was recommended, as well as the time to treatment initiation.

RESULTS

A total of 159 patients were included. The GO-MDT recommendation was favorable in 58% of cases, favorable with adjustment in 19%, and unfavorable in 23%. All treatment modifications recommended by the GO-MDT were treatment de-intensification strategies. In multivariable analysis, age>80 years and a low G8 score were independently associated with a favorable-with-adjustment or unfavorable recommendation. When treatment modification was recommended, the treatment ultimately delivered was consistent with the GO-MDT recommendation in 70% of cases. The median time from referral for geriatric assessment to treatment initiation was 4.1 weeks.

CONCLUSION

The GO-MDT recommended treatment de-intensification in more than 40% of cases, highlighting its value in personalizing cancer treatment for older adults.